VERTEX TO ACQUIRE CRINETICS PHARMACEUTICALS
VERTEX TO BUY CRINETICS FOR $85 PER SHARE IN $10 BILLION DEAL
VERTEX WILL ACQUIRE CRINETICS FOR $85.00 PER SHARE IN CASH
VERTEX TO FINANCE DEAL USING CASH ON HAND & DEBT
DEAL EXPECTED TO BE ACCRETIVE VERTEX'S TO NON-GAAP OPERATING INCOME IN 2029
FINANCING SUPPORTED BY $4.5 BILLION OF FULLY COMMITTED BRIDGE FINANCING FROM BANK OF AMERICA, MORGAN STANLEY SENIOR FUNDING
Reuters
Vertex To Acquire Crinetics Pharmaceuticals In $10 Billion Deal
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- NASDAQ:CRNX, NASDAQ:VRTX
- Language
- English (India)
VERTEX TO ACQUIRE CRINETICS PHARMACEUTICALSVERTEX TO BUY CRINETICS FOR $85 PER SHARE IN $10 BILLION DEALVERTEX WILL ACQUIRE CRINETICS FOR $85.00 PER SHARE IN CASHVERTEX TO FINANCE